VERNON HILLS, Ill., Nov. 10 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that Dina Grinshpun has joined the Company in the newly created position as Vice President, General and IP Counsel.
Ms. Grinshpun previously worked at Fish & Richardson P.C., one of the largest law firms in the world specializing in intellectual property, complex litigation, and technology law. She accumulated valuable experience litigating patent infringement suits in a variety of subject matters and drafting patent applications, opinion letters, and various agreements. Prior to joining Fish & Richardson P.C., Ms. Grinshpun was a judicial clerk for the Honorable Randall R. Rader at the United States Court of Appeals for the Federal Circuit, the court with exclusive jurisdiction over patent appeals. In addition, she has a strong technical background, having worked as a pharmaceutical chemist at Procter & Gamble Pharmaceuticals, Inc. prior to becoming an attorney.
Stephen Thompson, President and CEO of Immtech International, stated, “We are very excited to have someone with Dina’s expertise in intellectual property and legal affairs join our team. Dina will play an important roll in helping us negotiate joint venture and licensing agreements with potential strategic partners, as well as ensuring that the Company’s technology platform comprising of US and International patents, including but not limited to our library of over 2300 compounds licensed from our Scientific Consortium, is well protected.”
Ms. Grinshpun received her B.S. in Chemistry with honors from the University of Western Ontario and her Juris Doctorate from the University of Michigan Law School. She is a Member of the Bar of the State of California.
About Immtech International
Immtech International, Inc. is a pharmaceutical company working to commercialize oral drugs to treat infectious diseases and aims to expand the targeted markets by applying its proprietary aromatic cation technology platform to the treatment of cancer, diabetes and other disorders. Immtech has advanced clinical programs that include new treatments for malaria, Pneumocystis pneumonia (“PCP”) and African sleeping sickness (trypanosomiasis), and drug development programs for fungal infections and tuberculosis. The Company has worldwide licensing and exclusive commercialization rights to an aromatic cationic pharmaceutical technology platform and is developing drugs intended for commercial use based on that technology. For additional information, please go to http://www.immtech-international.com.
“Safe Harbor” Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the most recently ended fiscal year.
Immtech International, Inc.
CONTACT: F. C. Thompson, +1-877-898-8038
